[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:muscle-invasive-bladder-carcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Muscle Invasive Bladder Carcinoma",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06263153","Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy",[11],"Phase 2","RECRUITING","2026-08-26T02:17:16.126291Z","2026-05-05T02:43:27.135215Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06493552","Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors",[19],"Phase 2\u002FPhase 3","2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.133440Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT05790850","Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial)",[],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:29.163821Z",[],[]]